Compare New Era Energy & Digital Inc. Common Stock (NUAI) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New Era Energy & Digital Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $4.93 (market cap $668.01M), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 5.9× New Era Energy & Digital Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, New Era Energy & Digital Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| NUAI | RLAY | |
|---|---|---|
Market Cap | $668.01M | $3.94B |
Volume | 6,756,652 | 3,432,928 |
Sector | Technology | Health |
52-Week High | $8.06 | $20.75 |
52-Week Low | $2.35 | $6.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $613.36M | $3.06B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
